Boston Scientific EPS - Earnings per Share 2012-2026 | BSX
Boston Scientific annual and quarterly earnings per share history from 2012 to 2026. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Boston Scientific EPS for the quarter ending June 30, 2026 was $0.61, a 15.09% increase year-over-year.
- Boston Scientific EPS for the twelve months ending June 30, 2026 was $2.47, a 47.02% increase year-over-year.
- Boston Scientific 2025 annual EPS was $1.94, a 55.2% increase from 2024.
- Boston Scientific 2024 annual EPS was $1.25, a 16.82% increase from 2023.
- Boston Scientific 2023 annual EPS was $1.07, a 137.78% increase from 2022.
| Boston Scientific Annual EPS | |
|---|---|
| 2025 | $1.94 |
| 2024 | $1.25 |
| 2023 | $1.07 |
| 2022 | $0.45 |
| 2021 | $0.69 |
| 2020 | $-0.08 |
| 2019 | $3.33 |
| 2018 | $1.19 |
| 2017 | $0.08 |
| 2016 | $0.25 |
| 2015 | $-0.18 |
| 2014 | $-0.09 |
| 2013 | $-0.09 |
| 2012 | $-2.89 |
| 2011 | $0.29 |
| Boston Scientific Quarterly EPS | |
|---|---|
| 2026-06-30 | $0.61 |
| 2026-03-31 | $0.90 |
| 2025-12-31 | $0.45 |
| 2025-09-30 | $0.51 |
| 2025-06-30 | $0.53 |
| 2025-03-31 | $0.45 |
| 2024-12-31 | $0.38 |
| 2024-09-30 | $0.32 |
| 2024-06-30 | $0.22 |
| 2024-03-31 | $0.33 |
| 2023-12-31 | $0.34 |
| 2023-09-30 | $0.34 |
| 2023-06-30 | $0.18 |
| 2023-03-31 | $0.21 |
| 2022-12-31 | $0.09 |
| 2022-09-30 | $0.12 |
| 2022-06-30 | $0.17 |
| 2022-03-31 | $0.07 |
| 2021-12-31 | $0.06 |
| 2021-09-30 | $0.28 |
| 2021-06-30 | $0.12 |
| 2021-03-31 | $0.23 |
| 2020-12-31 | $0.14 |
| 2020-09-30 | $-0.12 |
| 2020-06-30 | $-0.11 |
| 2020-03-31 | $0.01 |
| 2019-12-31 | $2.83 |
| 2019-09-30 | $0.09 |
| 2019-06-30 | $0.11 |
| 2019-03-31 | $0.30 |
| 2018-12-31 | $0.27 |
| 2018-09-30 | $0.31 |
| 2018-06-30 | $0.40 |
| 2018-03-31 | $0.21 |
| 2017-12-31 | $-0.44 |
| 2017-09-30 | $0.20 |
| 2017-06-30 | $0.11 |
| 2017-03-31 | $0.21 |
| 2016-12-31 | $0.08 |
| 2016-09-30 | $0.17 |
| 2016-06-30 | $-0.15 |
| 2016-03-31 | $0.15 |
| 2015-12-31 | $-0.11 |
| 2015-09-30 | $-0.15 |
| 2015-06-30 | $0.08 |
| 2015-03-31 | $0.00 |
| 2014-12-31 | $-0.22 |
| 2014-09-30 | $0.03 |
| 2014-06-30 | $0.00 |
| 2014-03-31 | $0.10 |
| 2013-12-31 | $0.07 |
| 2013-09-30 | $0.00 |
| 2013-06-30 | $0.10 |
| 2013-03-31 | $-0.26 |
| 2012-12-31 | $0.02 |
| 2012-09-30 | $-0.48 |
| 2012-06-30 | $-2.51 |
| 2012-03-31 | $0.08 |
| 2011-12-31 | $0.07 |
| 2011-09-30 | $0.09 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $65.288B | $20.074B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||